Mobile

A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hip

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013329-41

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• Demonstrate superior analgesic efficacy of tanezumab 10 mg and 5 mg administered IV every 8 weeks compared to placebo at Week 16. • Demonstrate non-inferiority and, if warranted, superior analgesic efficacy of tanezumab 10 mg and 5 mg administered IV every 8 weeks compared to oxycodone HCl controlled release (CR) tablets (Oxycontin) 10-40 mg every 12 hours (q12h) at Week 16.

Critère d'inclusion

  • osteoarthritis of the knee and hip

Liens